United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $475.27, for a total value of $1,901,080.00. Following the transaction, the chief executive officer owned 130 shares in the company, valued at approximately $61,785.10. This represents a 96.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Trading Up 1.1%

NASDAQ UTHR traded up $5.21 on Friday, reaching $489.31. 303,005 shares of the company were exchanged, compared to its average volume of 582,184. The business’s fifty day moving average price is $451.78 and its 200 day moving average price is $366.63. The stock has a market capitalization of $21.07 billion, a P/E ratio of 18.54, a price-to-earnings-growth ratio of 4.78 and a beta of 0.86. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $492.62.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same quarter in the previous year, the firm earned $6.39 EPS. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. Equities research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on UTHR. Jefferies Financial Group reissued a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Morgan Stanley set a $447.00 target price on United Therapeutics in a research note on Wednesday, October 29th. Bank of America upped their price target on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. UBS Group raised their price objective on United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Finally, HC Wainwright upped their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $505.00.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently added to or reduced their stakes in UTHR. CWM LLC increased its position in shares of United Therapeutics by 204.3% in the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock valued at $1,492,000 after purchasing an additional 3,487 shares during the last quarter. AXQ Capital LP grew its stake in shares of United Therapeutics by 495.4% during the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock worth $1,117,000 after purchasing an additional 3,235 shares in the last quarter. XTX Topco Ltd purchased a new position in United Therapeutics in the first quarter valued at $313,000. LPL Financial LLC raised its stake in United Therapeutics by 77.3% in the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock valued at $7,783,000 after buying an additional 11,007 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in United Therapeutics by 77.4% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company’s stock worth $1,792,000 after buying an additional 2,655 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.